Page 0006

NEWS

The Committee for Medicinal Products

for Human Use (CHMP), under the

European Medicines Agency (EMA), has

recommended marketing authorisation

for Novo Nordisk Fiasp (fast-acting

insulin aspart) for use in the treatment of

adults with Type 1 and Type 2 diabetes.

The CHMP recommends Fiasp, the

intended brand name for fast-acting

insulin aspart, to be used as the bolus

component of basal-bolus therapy in

combination with basal insulin and for

continuous subcutaneous insulin infusion

via an insulin pump. Novo Nordisk has

developed Fiasp as mealtime insulin with

an earlier and greater glucose-lowering

effect than NovoRapid (insulin aspart).

"We believe Fiasp provides an

important evolution in mealtime insulin,

which can address the unmet medical

need for people requiring further

improved blood glucose control around

meals or flexibility of dosing," says Mads

FASTER INSULIN, SOON

Krogsgaard Thomsen, executive vice

president and chief science officer of

Novo Nordisk. It is expects to receive

final marketing authorisation from the

European Commission in the early part of

2017.

Meanwhile, Novo Nordisk has

submitted a New Drug Application (NDA)

to the US Food and Drug Administration

(FDA) and a Marketing Authorisation

Application (MAA) to the European

Medicines Agency (EMA) for semaglutide,

a new glucagon-like peptide-1 (GLP1) analogue administered

once-weekly,

for the treatment of adults with Type 2

diabetes. Semaglutide is a new onceweekly analogue of human GLP-1

that stimulates insulin and suppresses

glucagon secretion in a glucosedependent manner,

while decreasing

appetite and food intake. Novo Nordisk

intends to make once-weekly semaglutide

available in a prefilled delivery device

based on the same technology platform

as FlexTouch.

In addition, Novo Nordisk and Glooko

have announced that the two companies

will work together to deliver jointlydeveloped and branded digital health

solutions for people with diabetes. The

non-exclusive collaboration will combine

Novo Nordisk's deep knowledge of

diabetes with Glooko's digital platform

and data analytics expertise.

Commenting on the agreement,

Christian Kanstrup, senior vice president,

Strategy, Access & Marketing, Novo

Nordisk said: "We are excited to partner

with Glooko and to take another step

towards delivering digital health offerings

that help people with diabetes to improve

their blood glucose control. Working in

partnerships will furthermore enhance our

ability to demonstrate the real-world value

of our portfolio of diabetes treatments."

DESANG MAG VIDEO

Index

  1. Desang diabetes magazine diabetes information
  2. Accu-Chek Mobile blood glucose system
  3. Desang diabetes magazine diabetes information, Sue Marshall
  4. Desang diabetes magazine diabetes news
  5. Desang diabetes magazine diabetes news
  6. Page 0006
  7. Desang diabetes magazine diabetes news
  8. Diabetes kit
  9. Medtronic Minimed 640G insulin pump
  10. diabetes food news
  11. Ascensia Contour Diabetes blood test meters
  12. diabetes food news
  13. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  14. My diabetes kit Claire Pesterfield
  15. My diabetes kit Claire Pesterfield
  16. My diabetes kit Claire Pesterfield,
  17. Dr Claire Guest Medical Detection Dogs, hypo detection
  18. Medical Detection Dogs, hypo detection, hypo awareness, Type 1 diabetes
  19. Accu-Chek Mobile, Medical Detection Dogs
  20. Paul Coker, Peter Davies, diabetes
  21. Paul Coker, Peter Davies living with diabetes
  22. health benefits and the sugar tax, soft drinks levy
  23. OneTouch Reveal blood test meter and app
  24. Making Carbs Count winter salads
  25. Making Carbs Count winter salad
  26. Accu-Chek Mobile blood glucose system
  27. Accu-Chek Mobile blood glucose system
  28. Desang diabetes magazine

Related Issues